Releuko, a filgrastim biosimilar developed by Kashiv Biosciences and Amneal Pharmaceuticals, becomes the third filgrastim biosimilar to be approved by the FDA. Releuko, a filgrastim biosimilar ...

Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...

Approval was based on data demonstrating similarity between the 2 the biosimilar and reference product, Neupogen. Releuko, a leukocyte growth factor, is approved to: Decrease the incidence of ...

Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Filgrastim Biosimilars Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global filgrastim biosimilars market is ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing ...

“Releuko is our second U.S. biosimilar launch and represents the next step in building out our biosimilars business. This product is another important oncology therapeutic offering for providers and ...

RELEUKO references Neupogen®, and is expected to launch in the third quarter of 2022. RELEUKO is indicated for the treatment of neutropenia experienced by patients undergoing chemotherapy. It was ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License ...

RELEUKO is Amneal’s second U.S. biosimilar launch. As we previously reported, Amneal announced the launch of its first biosimilar in the U.S., ALYMSYS (bevacizumab-maly), on October 3, 2022.

Second of three approved U.S. oncology biosimilars Amneal expects to launch BRIDGEWATER, N.J., November 22, 2022--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") ...